FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jake Fullen

Research Profile

Living Beings

Chemicals & Drugs

Disorders

HTLV-I Infections

Anatomy

Genes & Molecular Sequences

Physiology

Transcription, Genetic

Co-author Network

Publications

TOP 3
Christophe Nicot; Miroslav Dundr; Julie M Johnson; Jake R Fullen; Norma Alonzo; Risaku Fukumoto; Gerald Princler; David Derse; Tom Misteli; Genoveffa Franchini
HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.
Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
T-cell control by human T-cell leukemia/lymphoma virus type 1.
Zdenek Hel; Elzbieta Tryniszewska; Wen-Po Tsai; Julie M Johnson; Robert Harrod; Jake R Fullen; Vaniambadi S Kalyanaraman; John D Altman; James McNally; Tatiana S Karpova; Barbara K Felber; Jim Tartaglia; Genoveffa Franchini
Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jake Fullen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Christophe Nicot; Miroslav Dundr; Julie M Johnson; Jake R Fullen; Norma Alonzo; Risaku Fukumoto; Gerald Princler; David Derse; Tom Misteli; Genoveffa Franchini
HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.
Nature medicine 2004;10(2):197-201.
2003: Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
T-cell control by human T-cell leukemia/lymphoma virus type 1.
International journal of hematology 2003;78(4):280-96.
2002: Zdenek Hel; Elzbieta Tryniszewska; Wen-Po Tsai; Julie M Johnson; Robert Harrod; Jake R Fullen; Vaniambadi S Kalyanaraman; John D Altman; James McNally; Tatiana S Karpova; Barbara K Felber; Jim Tartaglia; Genoveffa Franchini
Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.
DNA and cell biology 2002;21(9):619-26.
2002: Zdenek Hel; Julie M Johnson; Elzbieta Tryniszewska; Wen-Po Tsai; Robert Harrod; Jake R Fullen; Jim Tartaglia; Genoveffa Franchini
A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
Vaccine 2002;20(25-26):3171-86.
2001: Christophe Nicot; JC Mulloy; Maria Grazia Ferrari; Julie M Johnson; K Fu; Risaku Fukumoto; R Trovato; Jake R Fullen; Warren J Leonard; Genoveffa Franchini
HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells.
Blood 2001;98(3):823-9.
2001: Julie M Johnson; Christophe Nicot; Jake R Fullen; Vincenzo Ciminale; L Casareto; JC Mulloy; S Jacobson; Genoveffa Franchini
Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.
Journal of virology 2001;75(13):6086-94.
2000: Julie M Johnson; JC Mulloy; Vincenzo Ciminale; Jake R Fullen; Christophe Nicot; Genoveffa Franchini
The MHC class I heavy chain is a common target of the small proteins encoded by the 3' end of HTLV type 1 and HTLV type 2.
AIDS research and human retroviruses 2000;16(16):1777-81.
1998: JC Mulloy; T Kislyakova; A Cereseto; L Casareto; A LoMonico; Jake R Fullen; M V Lorenzi; Andrea Cara; Christophe Nicot; Chou-Zen Giam; Genoveffa Franchini
Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain.
Journal of virology 1998;72(11):8852-60.